Literature DB >> 12212839

Conditional over-expression of estrogen receptor alpha in a transgenic mouse model.

Kathleen S Hruska1, Maddalena T Tilli, Shuxun Ren, Ion Cotarla, Theresa Kwong, Minglin Li, Joseph D Fondell, Judy A Hewitt, Robert D Koos, Priscilla A Furth, Jodi A Flaws.   

Abstract

Attempts to delineate the mechanisms of estrogen action have promoted the creation of several estrogen receptor alpha (ERalpha) mouse models in the past decade. These traditional models are limited by the fact that the receptors are either absent or present throughout all stages of development. The purpose of this work was to develop a conditional transgenic model that would provide an in vivo method of controlling the spatial and temporal regulation of ERalpha expression. The tetracycline responsive system was utilized. Three lines of transgenic mice carrying a transgene composed of the coding sequence for murine ERalpha placed under the regulatory control of a tet operator promoter (tet-op) were generated. These three lines of tet-op-mERa mice were each mated to an established line of transgenic mice expressing a tetracycline-dependent transactivator protein (tTA) from the mouse mammary tumor virus-long terminal repeat (MMTV-LTR). Double transgenic MMTV-tTA/tet-op-mERalpha mice were produced. All three lines demonstrated dominant gain of ERalpha shown by RT-PCR, immunoprecipitation, and immunohistochemistry. Transgene-specific ERalpha was expressed in numerous tissues including the mammary gland, salivary gland, testis, seminal vesicle, and epididymis. Expression was silenced by administration of doxycycline in the drinking water. This model can be utilized to evaluate the consequences of ERalpha dominant gain in targeted tissues at specific times during development. In this study dominant gain of ERalpha was associated with a reduction in epididymal/vas deferens and seminal vesicle weights consistent with the proposed action of ERalpha on fluid transport in the male reproductive tract. Combining this model with other dominant gain and gene knockout mouse models will be useful for testing effects of ERalpha action in combination with specific gene products and to evaluate if developmental and stage-specific expression of ERalpha can rescue identified phenotypes in gene knockout mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12212839     DOI: 10.1023/a:1016376100186

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   3.145


  44 in total

1.  Tight control of gene expression in mammalian cells by tetracycline-responsive promoters.

Authors:  M Gossen; H Bujard
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

2.  Estrogen regulation of adipose tissue lipoprotein lipase--possible mechanism of body fat distribution.

Authors:  T M Price; S N O'Brien; B H Welter; R George; J Anandjiwala; M Kilgore
Journal:  Am J Obstet Gynecol       Date:  1998-01       Impact factor: 8.661

3.  Accelerated onset of uterine tumors in transgenic mice with aberrant expression of the estrogen receptor after neonatal exposure to diethylstilbestrol.

Authors:  J F Couse; V L Davis; R B Hanson; W N Jefferson; J A McLachlan; B C Bullock; R R Newbold; K S Korach
Journal:  Mol Carcinog       Date:  1997-08       Impact factor: 4.784

4.  Temporal control of the Cre recombinase in transgenic mice by a tetracycline responsive promoter.

Authors:  L St-Onge; P A Furth; P Gruss
Journal:  Nucleic Acids Res       Date:  1996-10-01       Impact factor: 16.971

Review 5.  Estrogen receptor interaction with estrogen response elements.

Authors:  C M Klinge
Journal:  Nucleic Acids Res       Date:  2001-07-15       Impact factor: 16.971

6.  Conditional expression of a Gi-coupled receptor causes ventricular conduction delay and a lethal cardiomyopathy.

Authors:  C H Redfern; M Y Degtyarev; A T Kwa; N Salomonis; N Cotte; T Nanevicz; N Fidelman; K Desai; K Vranizan; E K Lee; P Coward; N Shah; J A Warrington; G I Fishman; D Bernstein; A J Baker; B R Conklin
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

7.  Doxycycline control of prion protein transgene expression modulates prion disease in mice.

Authors:  P Tremblay; Z Meiner; M Galou; C Heinrich; C Petromilli; T Lisse; J Cayetano; M Torchia; W Mobley; H Bujard; S J DeArmond; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

8.  Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

Authors:  P A Furth; L St Onge; H Böger; P Gruss; M Gossen; A Kistner; H Bujard; L Hennighausen
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

9.  Aberrant reproductive phenotypes evident in transgenic mice expressing the wild-type mouse estrogen receptor.

Authors:  V L Davis; J F Couse; E H Goulding; S G Power; E M Eddy; K S Korach
Journal:  Endocrinology       Date:  1994-07       Impact factor: 4.736

10.  Glucocorticoid regulation of mouse mammary tumor virus sequences in transgenic mice.

Authors:  S R Ross; D Solter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

View more
  12 in total

1.  Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland.

Authors:  Nadia Okolowsky; Priscilla A Furth; Paul A Hamel
Journal:  Dev Biol       Date:  2014-04-21       Impact factor: 3.582

2.  A doxycycline-inducible, tissue-specific aromatase-expressing transgenic mouse.

Authors:  Jenny D Y Chow; John T Price; Margaret M Bills; Evan R Simpson; Wah Chin Boon
Journal:  Transgenic Res       Date:  2011-05-26       Impact factor: 2.788

Review 3.  Assessing estrogen signaling aberrations in breast cancer risk using genetically engineered mouse models.

Authors:  Priscilla A Furth; M Carla Cabrera; Edgar S Díaz-Cruz; Sarah Millman; Rebecca E Nakles
Journal:  Ann N Y Acad Sci       Date:  2011-07       Impact factor: 5.691

4.  Increased sensitivity of estrogen receptor alpha overexpressing antral follicles to methoxychlor and its metabolites.

Authors:  Tessie Paulose; Isabel Hernández-Ochoa; Mallikarjuna S Basavarajappa; Jackye Peretz; Jodi A Flaws
Journal:  Toxicol Sci       Date:  2011-01-20       Impact factor: 4.849

5.  Deregulated estrogen receptor alpha and p53 heterozygosity collaborate in the development of mammary hyperplasia.

Authors:  Edgar S Díaz-Cruz; Priscilla A Furth
Journal:  Cancer Res       Date:  2010-05-15       Impact factor: 12.701

6.  Comparison of increased aromatase versus ERα in the generation of mammary hyperplasia and cancer.

Authors:  Edgar S Díaz-Cruz; Yasuro Sugimoto; G Ian Gallicano; Robert W Brueggemeier; Priscilla A Furth
Journal:  Cancer Res       Date:  2011-08-15       Impact factor: 12.701

7.  Genetically induced estrogen receptor α mRNA (Esr1) overexpression does not adversely affect fertility or penile development in male mice.

Authors:  John Heath; Yazeed Abdelmageed; Tim D Braden; Carol S Williams; John W Williams; Tessie Paulose; Isabel Hernandez-Ochoa; Rupesh Gupta; Jodi A Flaws; Hari O Goyal
Journal:  J Androl       Date:  2010-10-07

8.  Introduction of estrogen receptor-alpha into the tTA/TAg conditional mouse model precipitates the development of estrogen-responsive mammary adenocarcinoma.

Authors:  Maddalena T Tilli; M Silvina Frech; Mary E Steed; Kathleen S Hruska; Michael D Johnson; Jodi A Flaws; Priscilla A Furth
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice.

Authors:  Xu Fang Pei; Marcia S Noble; Maria Antonietta Davoli; Edward Rosfjord; Maddalena T Tilli; Priscilla A Furth; Robert Russell; Michael D Johnson; Robert B Dickson
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Jan-Feb       Impact factor: 2.416

10.  Mouse models of estrogen receptor-positive breast cancer.

Authors:  Shakur Mohibi; Sameer Mirza; Hamid Band; Vimla Band
Journal:  J Carcinog       Date:  2011-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.